Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant dabrafenib + trametinib for BRAF V600E-mutant conventional ameloblastoma
ChiCTR2400094146Phase 2Recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dabrafenib + trametinib and trametinib in ameloblastoma, sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Tumor volume. Started Dec 2024; status: recruiting.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
ameloblastoma
Beyond the preview
Go deeper on ChiCTR2400094146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094146.